Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 3/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039300 | 0.88 | SLC1A5 (0.44) | SLC1A5NR1H3MEP1BALDH1A1TSHR | |
| SCHEMBL4048154 | 0.73 | BCHE (0.43) | BCHE | |
| SCHEMBL7591136 | 0.72 | KMT2A (0.42) | — | |
| SCHEMBL4047022 | 0.72 | CALM1 (0.55) | SLC1A5CALM1CAMKK2NR1H3MEP1B | |
| SCHEMBL4044417 | 0.72 | RORC (0.42) | SLC1A5NR1H3BCHEACHEL3MBTL1 | |
| SCHEMBL4041765 | 0.72 | ADRB3 (0.46) | ALDH1A1KDM4EACHE | |
| SCHEMBL8423493 | 0.69 | CALM1 (0.64) | SLC1A5CALM1CAMKK2MEP1BALDH1A1 | |
| SCHEMBL4041249 | 0.69 | MTNR1A (0.48) | BCHEL3MBTL1 | |
| SCHEMBL7054663 | 0.68 | DNM1 (0.55) | ALDH1A1KDM4EBCHECHRM2 | |
| SCHEMBL27593038 | 0.68 | DNM1 (0.55) | ALDH1A1KDM4EBCHECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612054-B2 | Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| EP-1651592-B1 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
| EP-1651592-A2 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014517-A2 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | APP, BACE1, BCHE | SLC1A5 907/4885CALM1 605/4885CAMKK2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.